Patents by Inventor Chamutal Gur

Chamutal Gur has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180333439
    Abstract: The present invention provides attenuated or inactivated pathogenic bacteria having anti-cancer properties, compositions comprising the bacteria, and use thereof for treating cancers of the urogenital system.
    Type: Application
    Filed: November 10, 2015
    Publication date: November 22, 2018
    Applicants: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Ofer MANDELBOIM, Gilad Benjamin BACHRACH, Chamutal GUR, Vladimir YUTKIN
  • Patent number: 8980244
    Abstract: The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.
    Type: Grant
    Filed: April 15, 2013
    Date of Patent: March 17, 2015
    Assignees: Ben-Gurion University of the Negev Research and Development Authority, Hadasit Medical Research Services and Development Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd.
    Inventors: Ofer Mandelboim, Angel Porgador, Yaakov Naparstek, Chamutal Gur
  • Publication number: 20130280209
    Abstract: The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.
    Type: Application
    Filed: April 15, 2013
    Publication date: October 24, 2013
    Inventors: Ofer MANDELBOIM, Angel PORGADOR, Yaakov NAPARSTEK, Chamutal GUR
  • Patent number: 8420092
    Abstract: The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.
    Type: Grant
    Filed: March 18, 2010
    Date of Patent: April 16, 2013
    Assignees: Ben-Gurion University of the Negev Research and Development Authority, Hadasit Medical Research Services and Development Ltd.
    Inventors: Ofer Mandelboim, Angel Porgador, Yaakov Naparstek, Chamutal Gur
  • Publication number: 20120076753
    Abstract: The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.
    Type: Application
    Filed: March 18, 2010
    Publication date: March 29, 2012
    Inventors: Ofer Mandelboim, Angel Porgador, Yaakov Naparstek, Chamutal Gur